165 related articles for article (PubMed ID: 16759701)
1. May the correlation between Kit-D816 mutation and AML1-ETO level change the use of prognostic factors in t(8;21) AML?
Potenza L; Luppi M; Riva G; Ottaviani E; Zucchini P; Morselli M; Volzone F; Forghieri F; Martinelli G; Torelli G
Leuk Res; 2007 Feb; 31(2):269-71. PubMed ID: 16759701
[No Abstract] [Full Text] [Related]
2. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
3. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec.
Wang YY; Zhou GB; Yin T; Chen B; Shi JY; Liang WX; Jin XL; You JH; Yang G; Shen ZX; Chen J; Xiong SM; Chen GQ; Xu F; Liu YW; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1104-9. PubMed ID: 15650049
[TBL] [Abstract][Full Text] [Related]
4. A new D816 c-KIT gene mutation in refractory AML1-ETO leukemia.
Lasa A; Carricondo MT; Carnicer MJ; Perea G; Aventín A; Nomdedeu JF
Haematologica; 2006 Sep; 91(9):1283-4. PubMed ID: 16956837
[TBL] [Abstract][Full Text] [Related]
5. High expression of c-kit mRNA predicts unfavorable outcome in adult patients with t(8;21) acute myeloid leukemia.
Gao X; Lin J; Gao L; Deng A; Lu X; Li Y; Wang L; Yu L
PLoS One; 2015; 10(4):e0124241. PubMed ID: 25860287
[TBL] [Abstract][Full Text] [Related]
6. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Schnittger S; Kohl TM; Haferlach T; Kern W; Hiddemann W; Spiekermann K; Schoch C
Blood; 2006 Mar; 107(5):1791-9. PubMed ID: 16254134
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
8. Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in complete hematologic remission.
Buonamici S; Ottaviani E; Visani G; Bonifazi F; Fiacchini M; Baccarani M; Martinelli G
Haematologica; 2004 Jan; 89(1):103-5. PubMed ID: 14754613
[No Abstract] [Full Text] [Related]
9. AML1-ETO positive AML: first report from India.
Dutta P; Hasan SK; Sazawal S; Kumar B; Bhattacharyya J; Jain M; Tyagi S; Kumar R; Pati HP; Saxena R
Indian J Pathol Microbiol; 2007 Jul; 50(3):652-4. PubMed ID: 17883173
[TBL] [Abstract][Full Text] [Related]
10. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2.
Jiao B; Wu CF; Liang Y; Chen HM; Xiong SM; Chen B; Shi JY; Wang YY; Wang JH; Chen Y; Li JM; Gu LJ; Tang JY; Shen ZX; Gu BW; Zhao WL; Chen Z; Chen SJ
Leukemia; 2009 Sep; 23(9):1598-604. PubMed ID: 19458628
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of the AML1-ETO fusion transcript expression in children and young adults with t(8;21) acute myeloid leukemia.
Fleischman EW; Baturina JA; Sokova OI; Popa AV; Kosorukova IS; Rowley JD
Haematologica; 2003 Sep; 88(9):1078-9. PubMed ID: 12969821
[No Abstract] [Full Text] [Related]
12. AML with t(8;21) and trisomy 4: possible involvement of c-kit?
Langabeer SE; Beghini A; Larizza L
Leukemia; 2003 Sep; 17(9):1915; author reply 1915-6. PubMed ID: 12970800
[No Abstract] [Full Text] [Related]
13. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Jul; 37(7):784-9. PubMed ID: 23528260
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
De J; Zanjani R; Hibbard M; Davis BH
Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
16. Quantitative nested reverse transcriptase PCR vs. real-time PCR for measuring AML1/ETO (MTG8) transcripts.
Takenokuchi M; Yasuda C; Takeuchi K; Nakamachi Y; Mukai M; Kondo S; Kumagai S; Saigo K; Murayama T; Koizumi T; Tatsumi E
Clin Lab Haematol; 2004 Apr; 26(2):107-14. PubMed ID: 15053804
[TBL] [Abstract][Full Text] [Related]
17. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells.
Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ
J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927
[TBL] [Abstract][Full Text] [Related]
18. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO.
Kuchenbauer F; Schnittger S; Look T; Gilliland G; Tenen D; Haferlach T; Hiddemann W; Buske C; Schoch C
Br J Haematol; 2006 Sep; 134(6):616-9. PubMed ID: 16938118
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia with t(8;21)/AML1/ETO: a distinct biological and clinical entity.
Ferrara F; Del Vecchio L
Haematologica; 2002 Mar; 87(3):306-19. PubMed ID: 11869944
[TBL] [Abstract][Full Text] [Related]
20. A novel exon in AML1-ETO negatively influences the clonogenic potential of the t(8;21) in acute myeloid leukemia.
Mannari D; Gascoyne D; Dunne J; Chaplin T; Young B
Leukemia; 2010 Apr; 24(4):891-4. PubMed ID: 20111069
[No Abstract] [Full Text] [Related]
[Next] [New Search]